This post was originally published on this site Xynomic Pharma has initiated patient dosing in a Phase 1/2 trial testing its investigational therapy abexinostat, in combination with Imbruvica (ibrutinib), as a treatment for people with mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) who failed prior lines of treatment, the company announced. The trial (NCT03939182),…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
EMA Committee Favors Keytruda-Inlyta Combo for Advanced Kidney Cancer Patients
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that a combination of Keytruda (pembrolizumab) and Inlyta (axitinib) be approved as a first-line treatment for advanced renal cell carcinoma, the most common type of kidney cancer. The European Commission is now reviewing…
Verzenio-Faslodex Combo Prolongs Survival in Advanced Breast Cancer, Interim Phase 3 Data Show
This post was originally published on this site Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative advanced or metastatic breast cancer who had been previously treated with endocrine therapy, interim analysis of a Phase 3 trial shows. Verzenio is a cancer medication marketed by Eli Lilly. It is…
FDA Approves Nubeqa Tablets for Men with Non-metastatic Castration-resistant Prostate Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Nubeqa (darolutamide) tablets to treat men with non-metastatic castration-resistant prostate cancer (nmCRPC). “We know that men with nmCRPC are still in the prime of their lives and are at a critical point in their disease when action needs…
Allergan Issues Worldwide Recall of Some Breast Implant Products Due to Lymphoma Risk
This post was originally published on this site Allergan has issued a worldwide recall of its BIOCELL textured breast implant products, due to the potential risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The recall — for Allergan’s proprietary textured breast implants and tissue expanders — follows a request by the U.S. Food and Drug Administration…
Invitae Offers Free Genetic Testing, Counseling for Hereditary Prostate Cancer
This post was originally published on this site Invitae has launched a free genetic testing program to help connect prostate cancer patients to earlier diagnosis and treatments. The program also offers eligible patients free genetic counseling to help them understand their test results so that they can make more informed decisions about medical care. Called…
NHS England to Cover Lynparza Earlier in Advanced OC Treatment
This post was originally published on this site Maintenance treatment with Lynparza (olaparib) is now recommended after response to the first round of platinum-based chemotherapy in women with advanced ovarian cancer on England’s National Health Service (NHS). The decision by the National Institute for Health and Care Excellence (NICE) means that patients with BRCA mutations may receive Lynparza…
Donor-derived CAR T-cell Therapy ALLO-715 Enters Clinical Testing for Multiple Myeloma
This post was originally published on this site Allogene Therapeutics is launching the first clinical trial testing ALLO-715, its “off-the-shelf” CAR T-cell therapy, for people with multiple myeloma who failed prior therapies. This follows the recent approval by the U.S. Food and Drug Administration of an investigational new drug (IND) application for ALLO-715. The trial…
FDA Grants Breakthrough Therapy Status to Lenvima-Keytruda Combo for Advanced Liver Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) as a first-line treatment for patients with advanced unresectable hepatocellular carcinoma (HCC) that is not suitable for localized treatment. The designation of breakthrough therapy is given…
Team Will Use $10K Award to Bring Anti-lymphedema Bra to Market
This post was originally published on this site A team of recent University of Iowa (UI) graduates who designed a bra to help breast cancer patients prevent a condition called lymphedema will use a $10,000 award to try to commercialize the undergarment. The prize from the Victoria’s Secret Pink GRL PWR Project will enable the…
Rare Case of Spinal Sarcoidosis Provides Guidelines for Diagnosis, Management
This post was originally published on this site A new report describes a woman with a very rare case of sarcoidosis involving only the spine who entered full remission after surgical removal of the lesion followed by treatment with corticosteroids. Based on this case report, researchers advised that cases of spinal sarcoidosis should be managed…
FDA Approves Rituxan Biosimilar Ruxience for Non-Hodgkin’s Lymphoma
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for all non-Hodgkin’s lymphoma indications of its reference product, the company announced. The therapy was also approved for people with chronic lymphocytic leukemia (CLL), as well as granulomatosis with polyangiitis (GPA)…